Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225903 | 0.83 | BRAF (0.41) | BRAFRAF1 | |
| SCHEMBL12671174 | 0.82 | BRAF (0.45) | BRAFRAF1 | |
| SCHEMBL13225904 | 0.81 | BRAF (0.45) | BRAFRAF1 | |
| SCHEMBL12671534 | 0.75 | CDK4 (0.39) | BRAF | |
| SCHEMBL13225923 | 0.68 | MAP4K1 (0.41) | — | |
| SCHEMBL13225922 | 0.68 | MAP4K1 (0.39) | — | |
| SCHEMBL1571409 | 0.67 | MAP4K1 (0.42) | — | |
| SCHEMBL12671538 | 0.67 | BRAF (0.50) | BRAF | |
| SCHEMBL1570948 | 0.66 | BRAF (0.50) | BRAF | |
| SCHEMBL12671465 | 0.66 | ALK (0.41) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BRAF 316/4885RAF1 143/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | BRAF 208/4885RAF1 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.